A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
STUDY BACKGROUND:
This research will involve patients with glioblastoma. The drug bevacizumab (Avastin) is FDA
approved for the treatment of glioblastoma that gets worse after standard therapy. For
glioblastoma, bevacizumab is given by vein every 14 days. The purpose of this study is to see
if bevacizumab works as well when it is given as a daily subcutaneous shot as it does when
given intravenously. A subcutaneous shot is like an insulin shot or a heparin shot. The dose
of bevacizumab given on this study is in total slightly lower than the FDA approved dose for
glioblastoma.
STUDY DESCRIPTION:
About 10 people will take part in the study. Participants or caregivers will be educated on
injection and given prefilled syringes to take home. Participants or caregivers will
administer bevacizumab subcutaneously each day. The bevacizumab will be stored in the
refrigerator.
Follow up visits will be weekly for the first 3 weeks, then every 3 weeks. After 18 weeks,
the follow up interval can be increased to every 6 weeks at the treating physician's
discretion.
Participants can keep taking the bevacizumab until:
- Tests show that they are not benefiting from it,
- The participant has a bad side effect related to study treatment,
- The participant can no longer comply with study requirements, or
- The participant or doctor feels it is no longer in the participant's best interest.